Search bioRxiv⌕ Search

Biology subjects

Rusz, M.

Publications and source records attributed to Rusz, M..

3 recordsLinked to original sources

Benchmarking feature quality assurance strategies for non-targeted metabolomics

Automated data pre-processing (DPP) forms the basis of any liquid chromatography-high resolution mass spectrometry-driven non-targeted metabolomics experiment. However, current strategies for quality control of this important step have rarely been investigated or even discussed. We exemplified how reliable benchmark peak lists could be generated for eleven publicly available datasets acquired across different instrumental platforms. Moreover, we demonstrated how these benchmarks can be utilized to derive performance metrics for DPP and tested whether these metrics can be generalized for entire datasets. Relying on this principle, we cross-validated different strategies for quality assurance of DPP, including manual parameter adjustment, variance of replicate injection-based metrics, unsupervised clustering performance, automated parameter optimization, and deep learning-based classification of chromatographic peaks. Overall, we want to highlight the importance of assessing DPP performance on a regular basis.

bioinformatics↗

Thermodynamic genome-scale metabolic modeling of metallodrug resistance in colorectal cancer

BackgroundMass spectrometry-based metabolomics approaches provide an immense opportunity to enhance our understanding of the mechanisms that underpin the cellular reprogramming of cancers. Accurate comparative metabolic profiling of heterogeneous conditions, however, is still a challenge. MethodsMeasuring both intracellular and extracellular metabolite concentrations, we constrain four instances of a thermodynamic genome-scale metabolic model of the HCT116 colorectal carcinoma cell line to compare the metabolic flux profiles of cells that are either sensitive or resistant to ruthenium- or platinum-based treatments with BOLD-100/KP1339 and oxaliplatin, respectively. ResultsNormalizing according to growth rate and normalizing resistant cells according to their respective sensitive controls, we are able to dissect metabolic responses specific to the drug and to the resistance states. We find the normalization steps to be crucial in the interpretation of the metabolomics data and show that the metabolic reprogramming in resistant cells is limited to a select number of pathways. ConclusionsHere we elucidate the key importance of normalization steps in the interpretation of metabolomics data, allowing us to uncover drug-specific metabolic reprogramming during acquired metal-drug resistance.

cancer biology↗

STAT3-dependent systems-level analysis reveals PDK4 as an independent predictor of biochemical recurrence in prostate cancer

Prostate cancer (PCa) has a broad spectrum of clinical behaviour, hence biomarkers are urgently needed for risk stratification. We previously described the protective effect of STAT3 in a prostate cancer mouse model. By utilizing a gene co-expression network in addition to laser microdissected proteomics from human and murine prostate FFPE samples, we describe STAT3-induced downregulation of the TCA cycle/OXPHOS in PCa on transcriptomic and proteomic level. We identify pyruvate dehydrogenase kinase 4 (PDK4), a key regulator of the TCA cycle, as a promising independent prognostic marker in PCa. PDK4 predicts disease recurrence independent of diagnostic risk factors such as grading, staging and PSA level. Furthermore, PDK4 expression is causally linked to type 2 diabetes mellitus, which is known to have a protective effect on PCa. We conclude that this effect is related to PDK4 expression and that PDK4 loss could serve as a biomarker for PCa with dismal prognosis.

cancer biology↗